Ongoing clinical trials of apolipoprotein C3 and angiopoietin-like 3 inhibition will provide further valuable information on whether substantial remnant cholesterol-lowering therapy can prevent ASCVD in diabetes, and if there are no adverse effects such as LDL-cholesterol and apolipoprotein B increases, they may provide novel treatment options [41]. The gene discussed is APOC3; the disease is atherosclerosis.